Critique of the American Society of Clinical Oncology Value Assessment Framework for Cancer Treatments: Putting Methodologic Robustness First.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

1. Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries.The European journal of health economics : HEPAC : health economics in prevention and care · 2018
   Pooled it
2. Micrometastasis-derived models enable drug testing for early-stage, high-risk melanoma patients.EMBO molecular medicine · 2026
   Article
3. Should We Consider Value Frameworks for Cancer Drugs as Oncology's Landscape Evolves?; from an Oncologist Perspective in Korea.Journal of Korean medical science · 2021
   Article
4. Targeted therapies for renal cell carcinoma.Nature reviews. Nephrology · 2017
   Review
5. The Importance of Economic Perspective and Quantitative Approaches in Oncology Value Frameworks of Drug Selection and Shared Decision Making.Journal of managed care & specialty pharmacy · 2017
   Article
6. Evaluating Frameworks That Provide Value Measures for Health Care Interventions.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2017
   Article
7. Evaluating the Benefits of New Drugs in Health Technology Assessment Using Multiple Criteria Decision Analysis: A Case Study on Metastatic Prostate Cancer With the Dental and Pharmaceuticals Benefits Agency (TLV) in Sweden.MDM policy & practice
   Article

Corrections and comments

• Comment on
  Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.2016

Authors and funding

2 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as